Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | LSS | P48449 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9469406 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4MGLLLSS | |
| SCHEMBL9469447 | 0.82 | LSS (0.55) | LSS | |
| SCHEMBL3844537 | 0.80 | USP30 (0.45) | SLC6A2SLC6A3 | |
| SCHEMBL3238913 | 0.79 | LSS (0.49) | LSS | |
| SCHEMBL1848679 | 0.79 | CHRM2 (0.47) | SLC6A2SLC6A3SLC6A4LSS | |
| SCHEMBL13495085 | 0.79 | ALDH1A1 (0.55) | SLC6A2SLC6A3SLC6A4LSS | |
| SCHEMBL9469879 | 0.79 | CHRNB2 (0.48) | SLC6A2SLC6A3SLC6A4LSS | |
| SCHEMBL3238906 | 0.79 | LSS (0.49) | LSS | |
| SCHEMBL3215247 | 0.79 | TSHR (0.56) | SLC6A2SLC6A3SLC6A4LSS | |
| SCHEMBL1849637 | 0.79 | CHRM2 (0.47) | SLC6A2SLC6A3SLC6A4LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | ARGENTA DISCOVERY LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | ARGENTA DISCOVERY LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2008099186-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051405-A1 | Therapeutic Agents | GPR119, HTT, IAPP | SLC6A2 1701/4885SLC6A3 839/4885SLC6A4 1751/4885 |
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | CHRM2, CHRM3, CHRM1 | SLC6A2 2540/4885SLC6A3 1295/4885SLC6A4 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.